‘We remain very worked up about our scientific data and Calando’s ability to solve the most critical want of RNAi therapeutics, an effective and well tolerated delivery technique. As we function to complete the current trial, we remain self-confident that extra data will better serve our partnering goals given the continued urge for food for systemic RNAi delivery backed by solid clinical data.’ Pursuant a purchase contract between Calando and Arrowhead, Arrowhead purchased approximately 60 million shares of preferred stock in Calando for $1 million in cash and the cancellation of $8 million with debt owed to Arrowhead by Calando.. Arrowhead increases possession in Calando’s outstanding collateral to 79 percent Arrowhead Research Corporation today announced that it has invested $1 million in its bulk owned subsidiary, Calando Pharmaceuticals, and converted approximately $8M of Calando debt to Arrowhead into collateral.General survival at 2 yrs was high at 84 %. Koreth said a randomized trial of bortezomib for GVHD avoidance can be ongoing at Dana-Farber.. Alternative nonsurgical method to treat chronic tendinosis Researchers have found an alternative solution, ‘nonsurgical’ method to deal with chronic tendinosis of the Calf msucles that fails conservative treatment, according to a study performed in the Feinberg School of Medicine, Northwestern University in Chicago, IL. Seventeen sufferers underwent sonographically-guided Achilles tendon debridement, a procedure that helps to break up any scar tissue within the tendon that might cause it to become stiffer than regular and to encourage your body’s own repair process to heal the tendon harm.